4.6 Article

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles

期刊

CANCERS
卷 10, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/cancers10110416

关键词

scanning electron microscopy (SEM); circulating tumor cell (CTC); tumor-derived extracellular vesicle (tdEV); ferrofluid; CellSearch; microsieves

类别

资金

  1. NWO Applied and Engineering Sciences [14190]
  2. Cancer Research UK
  3. Prostate Cancer Foundation
  4. ECMC
  5. Movember
  6. Prostate Cancer UK

向作者/读者索取更多资源

To explore morphological features of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs), we developed a protocol for scanning electron microscopy (SEM) of CTCs and tdEVs. CTCs and tdEVs were isolated by immunomagnetic enrichment based on their Epithelial Cell Adhesion Molecule (EpCAM) expression or by physical separation through 5 mu m microsieves from 7.5 mL of blood from Castration-Resistant Prostate Cancer (CRPC) patients. Protocols were optimized using blood samples of healthy donors spiked with PC3 and LNCaP cell lines. CTCs and tdEVs were identified among the enriched cells by fluorescence microscopy. The positions of DNA+, CK+, CD45- CTCs and DNA-, CK+, CD45- tdEVs on the CellSearch cartridges and microsieves were recorded. After gradual dehydration and chemical drying, the regions of interest were imaged by SEM. CellSearch CTCs retained their morphology revealing various shapes, some of which were clearly associated with CTCs undergoing apoptosis. The ferrofluid was clearly distinguishable, shielding major portions of all isolated objects. CTCs and leukocytes on microsieves were clearly visible, but revealed physical damage attributed to the physical forces that cells exhibit while entering one or multiple pores. tdEVs could not be identified on the microsieves as they passed through the pores. Insights on the underlying mechanism of each isolation technique could be obtained. Complete detailed morphological characteristics of CTCs are, however, masked by both techniques.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Oncology phase I trial design and conduct: time for a change- MDICT Guidelines 2022

D. Araujo, A. Greystoke, S. Bates, A. Bayle, E. Calvo, L. Castelo-Branco, J. de Bono, A. Drilon, E. Garralda, P. Ivy, O. Kholmanskikh, I. Melero, G. Pentheroudakis, J. Petrie, R. Plummer, S. Ponce, S. Postel-Vinay, L. Siu, A. Spreafico, A. Stathis, N. Steeghs, C. Yap, T. A. Yap, M. Ratain, L. Seymour

Summary: In 2021, the FDA Oncology Center of Excellence launched Project Optimus to optimize dosage for oncology drugs. The MDICT Taskforce reviewed and discussed dosage optimization for oncology trials, providing recommendations for trial design and a practical guide for phase I trials. The aim is to improve dosage selection in early clinical trials of new anticancer treatments and ultimately enhance patient outcomes.

ANNALS OF ONCOLOGY (2023)

Article Oncology

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington

Summary: This study evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying BRCA1, BRCA2, and ATM alterations in patients with metastatic castration-resistant prostate cancer. The results showed that ctDNA detection can complement tissue testing and serve as a valuable alternative for patients with no or insufficient tissue for genomic analyses.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yuksel Urun, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain

Summary: The purpose of this study was to evaluate the use of ctDNA testing as an alternative method to identify mCRPC patients with HRR gene alterations who may benefit from olaparib treatment. The results showed that ctDNA testing can be a suitable alternative when tissue testing is not feasible or has failed.

CLINICAL CANCER RESEARCH (2023)

Article Urology & Nephrology

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhofer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono

Summary: This study evaluated the efficacy and safety of pembrolizumab plus olaparib in previously treated patients with metastatic castration-resistant prostate cancer. The results demonstrated antitumor activity and expected safety of this combination therapy in patients.

EUROPEAN UROLOGY (2023)

Article Urology & Nephrology

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin

Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.

EUROPEAN UROLOGY (2023)

Editorial Material Urology & Nephrology

A Transgender Patient with Prostate Cancer: Lessons Learnt

Khobe Chandran, Rafael Grochot, Maria de Los Dolores Fenor De La Maza, Wei Yuan, Bora Gurel, Susana Miranda, Alec Paschalis, Ruth Riisnaes, Ines Figueiredo, Denisa Bogdan, Adam Sharp, Suzanne Carreira, Johann S. de Bono

EUROPEAN UROLOGY (2023)

Correction Urology & Nephrology

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)

Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhoefer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono

EUROPEAN UROLOGY (2023)

Article Biochemistry & Molecular Biology

Critical role of antioxidant programs in enzalutamide-resistant prostate cancer

Eliot B. Blatt, Karla Parra, Antje Neeb, Lorenzo Buroni, Denisa Bogdan, Wei Yuan, Yunpeng Gao, Collin Gilbreath, Alec Paschalis, Suzanne Carreira, Ralph J. DeBerardinis, Ram S. Mani, Johann S. de Bono, Ganesh V. Raj

Summary: Therapy resistance to enzalutamide, a second-generation androgen receptor antagonist, is common in advanced prostate cancer (PCa) patients. This resistance is associated with higher levels of reactive oxygen species (ROS) and enhanced glutamine metabolism. Inhibiting glutamine metabolism or targeting antioxidant pathways can block the growth of enzalutamide-resistant PCa cells.

ONCOGENE (2023)

Article Medicine, General & Internal

SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol

Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander, Andrew Kightley, Jeffry Evans, Shing Lee, Alun Bedding, Sally Hopewell, Khadija Rantell, Rong Liu, An-Wen Chan, Johann De Bono, Christina Yap

Summary: The DEFINE study aims to improve the transparency, completeness, reproducibility, and interpretation of EPDF trial protocols (SPIRIT-DEFINE) and their reports (CONSORT-DEFINE). An extensive review of published trials and consultation with international experts will be conducted to refine the guidelines. The final version of the guidelines will be determined through a modified Delphi process and an international consensus meeting.

BMJ OPEN (2023)

Article Medicine, General & Internal

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap

Summary: This study aims to develop guidelines for early phase dose-finding trials through reviewing published trial reports and conducting a Delphi process. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines were developed, and a lay summary toolkit was created through patient and public involvement.

BMC MEDICINE (2023)

Article Oncology

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono

Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.

BRITISH JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-increment 11q splice variant

Stephen J. Pettitt, Nan Shao, Diana Zatreanu, Jessica Frankum, Ilirjana Bajrami, Rachel Brough, Dragomir B. Krastev, Theodoros I. Roumeliotis, Jyoti S. Choudhary, Sonja Lorenz, Alistair Rust, Johann S. de Bono, Timothy A. Yap, Andrew N. J. Tutt, Christopher J. Lord

Summary: Reduced expression of HUWE1 leads to increased levels of BRCA1- increment 11q and PARPi resistance. This effect is specific to cells able to express BRCA1- increment 11q and is not seen in other BRCA1 or BRCA2 mutant cells. HUWE1 silencing also restores RAD51 nuclear foci and platinum salt resistance, indicating its potential as a biomarker for PARPi resistance in future clinical trials.

ONCOGENE (2023)

Article Medicine, General & Internal

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J. Weir

Summary: The CONSORT-DEFINE guidance provides comprehensive reporting guidelines for early phase dose-finding trials, aiming to improve the quality of reporting and facilitate result interpretation.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

A systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in fabry disease

Ashwin Roy, Ravi Vijapurapu, Tarekegn Geberhiwot, Joseph De Bono, Adrian Warfield, Richard Steeds, Derralynn Hughes, James Moon, Polyvios Demetriades, Peter Woolfson

Article Oncology

Systematic study of tissue factor expression in solid tumors

Johann S. de Bono, Jeffrey R. Harris, Saskia M. Burm, Adriaan Vanderstichele, Mischa A. Houtkamp, Saida Aarass, Ruth Riisnaes, Ines Figueiredo, Daniel Nava Rodrigues, Rossitza Christova, Siel Olbrecht, Hans W. M. Niessen, Sigrid R. Ruuls, Danita H. Schuurhuis, Jeroen J. Lammerts van Bueren, Esther C. W. Breij, Ignace Vergote

Summary: This study compares the expression of tissue factor (TF) across various solid tumor types using immunohistochemistry. The results show that TF is expressed in multiple solid cancers and remains present during tumor dissemination and treatment.

CANCER REPORTS (2023)

暂无数据